Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.
Loading...
Embargo End Date
ICR Authors
Authors
Faustini, SE
Hall, A
Brown, S
Roberts, S
Hill, H
Stamataki, Z
(PITCH) consortium,
Jenner, MW
Owen, RG
Pratt, G
Cook, G
Richter, A
Drayson, MT
Kaiser, MF
Heaney, JLJ
Hall, A
Brown, S
Roberts, S
Hill, H
Stamataki, Z
(PITCH) consortium,
Jenner, MW
Owen, RG
Pratt, G
Cook, G
Richter, A
Drayson, MT
Kaiser, MF
Heaney, JLJ
Document Type
Journal Article
Date
2023-06-01
Date Accepted
2023-02-14
Abstract
Multiple myeloma (MM) and anti-MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID-19) and other infections. We investigated anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies longitudinally in ultra-high-risk patients with MM receiving risk-adapted, intensive anti-CD38 combined therapy in the Myeloma UK (MUK) nine trial. Despite continuous intensive therapy, seroconversion was achieved in all patients, but required a greater number of vaccinations compared to healthy individuals, highlighting the importance of booster vaccinations in this population. Reassuringly, high antibody cross-reactivity was found with current variants of concern, prior to Omicron subvariant adapted boostering. Multiple booster vaccine doses can provide effective protection from COVID-19, even with intensive anti-CD38 therapy for high-risk MM.
Citation
British Journal of Haematology, 2023, 201 (5), pp. 845 - 850
Source Title
British Journal of Haematology
Publisher
WILEY
ISSN
0007-1048
eISSN
1365-2141
1365-2141
1365-2141
Collections
Research Team
Myeloma Molecular Therapy